Install
Will the FDA approve any psychedelic substance for medical use before 2028?
The odds
How the odds have moved
Yes: 70% on Oct 21, 78% now.
Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.
Every outcome
| Outcome | Chance | Day | Bid | Ask | Pays | Contracts |
|---|---|---|---|---|---|---|
| Yes | 78% | 74¢ | 82¢ | $1.22 | 421 |
"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".
The news: FDA
Search ›- FDA grants tentative approval to low-cost HIV shotThe potential rollout of a more affordable injection to help prevent HIV infection lifts hopes for reduced AIDS deaths in Africa. US regulatorsâ approval of a cheaper HIV shot has lifted hopes in some of the worldâs poorest countries…
- FDA probes tumour risk tied to Novartis gene therapyTradingView FDA probes tumour risk tied to Novartis gene therapy
- FDA Upgrades Recall of Gelatelli-Brand GelatoThe lot of Gelatelli coffee and vanilla gelato that was withdrawn from the market last month was flagged by the U.S. Food and Drug Administration (FDA) as a Class I recall event this week. Concerns about the potential for Listeria…
- Novartis Gene Therapy Under FDA ScrutinyReuters The US Food and Drug Administration said on Friday it was investigating a risk... The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or tumour formation including malignancy, associated…
- Hutchmed China's sovleplenib designated orphan drug by FDAHutchmed China Ltd - Hong Kong-based biopharmaceutical company - Says its autoimmune hemolytic anemia medication sovleplenib was granted orphan drug designation by the US Food & Drug Administration.... Hutchmed China Ltd - Hong Kong-based…
- FDA Investigates Cancer Risk Associated With Novartis' Zolgensma Gene TherapyIn medicine, one truth transcends time: a drug's worth is measured not merely by how effectively it fights disease, but also by how safely it does so. One medicine that has recently drawn the FDA's attention over emerging safety concerns…
- FDA Approves Amivantamab for Recurrent or Metastatic HNSCCFDA grants accelerated approval to amivantamab and hyaluronidase-lpuj for recurrent or metastatic head and neck squamous cell carcinoma. The approval was based on cohort 1 of the open-label, multicenter phase 1b/2 OrigAMI-4 trial, which…
- FDA Recall Update: FebruaryThere were 14 recalls in the food & beverage, pet food, and drugs sectors, a 25% decrease compared with last month. The US Food & Drug Administration (FDA) recalled 14 food and beverage, pet food, and drugs products, and updated a previous…
- Maharashtra FDA Declares Wellness Capsules Spurious After Detecting Undisclosed Erectile Dysfunction DrugMumbai, November 7, 2026: A capsule marketed as Urja Urbpro has been declared spurious after laboratory tests detected tadalafil, a prescription drug commonly used to treat erectile dysfunction, in the product without it being declared as…
- FlowStop Hemostatic Spray Hits 18,000 Units, Seeks FDA ClearanceSouth Korean maker INNOPHARMA designs the no-compression liquid spray for bystanders, firefighters and soldiers who reach injuries before medical care DAEGU, South Korea, Nov. 6, 2026 /PRNewswire/ -- A liquid spray lets people without…
- Pharma critic Bernie Sanders is set to hold major sway over FDA funding billSTAT WASHINGTON – Democrats’ landslide victory in the midterm elections may have significant implications for the upcoming negotiations over a key funding source for the Food and Drug Administration in part by empowering a major critic of…
- FDA Puts Smoked Salmon Recall in Highest Risk Category Over ListeriaA recall of cold-smoked salmon has received the Food and Drug Administration’s highest risk rating after the product was found to be contaminated with bacteria that can cause serious illness or death. Under the FDA's recall definitions…
Related markets
All fda & drugs ›When will Compass Pathways submit a NDA for COMP360 psilocybin? (COMP360 psilocybin - NDA)
- before December98%▲ 6
- before 202798%▲ 5
- before April 202798%
Will the FDA approve retatrutide? (retatrutide (LY3437943))
- Before Jan 1, 20272%
- Before Jul 1, 202712%▼ 9
- Before Jan 1, 202856%
2 more
- Before Jul 1, 202885%
- Before Jan 1, 202990%
When will the FDA reclassify BPC-157 to Category 1?
- Before 202710%▲ 1
When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)
- Before 202890%▼ 1
- Before October 202788%▼ 1
- Before July 202787%
2 more
- Before Mar 1, 202765%▼ 1
- Before Jan 1, 202719%▲ 2
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Progressives. Prices read from the venues 4 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.
Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Progressives, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Progressives index; prices of stocks, rates and coins from 4Progressives Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions